QHFRX Mutual Fund

NAV$11.57

Fund Essentials - as of Sep 30, 2025

Net Assets
$54,618.52
Expense Ratio
8.54%
Dividend Yield (Current)
-
Holdings
788
Inception Date
Jun 16, 2025
Fund Family
AQR Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO

Performance

YTD-2.12%
1 Year+12.76%

Asset Allocation

Stocks: 60.04%
Bonds: 39.96%

Price Chart (6M)

View Full Chart →

Top Holdings

View All →
TickerNameWeight
-Limited Purpose Cash Investment Fund, 4.13%26.81%
-Fannie Mae Pool Fm9530 2.50% 7/1/20517.59%
-Goldman Sachs Financial Square Treasury Instruments Fund, Institutional Shares, 3.93%1.24%
-U.S. Treasury Inflation-Linked Notes 2.13%, 1/15/20350.81%
NOVN:SMNovartis Ag Chf0.49 (Regd)0.45%
Top 10 Concentration: 38.54%Report Date: Sep 30, 2025
Download all 788 holdings for QHFRX
CSV export with sector, industry & share changes
Get CSV

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how QHFRX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

QHFRX Mutual Fund Overview

QHFRX Mutual Fund (AQR MS Fusion HV Fund Class R6) is managed by AQR Funds with $54,618.52 in net assets. QHFRX expense ratio is 8.54%, holding 788 positions across sectors including Other, Unknown, Information Technology. Inception date: 2025-06-16.

QHFRX performance shows a YTD return of -2.12%. The 1-year return is 12.76%.

QHFRX top holdings include Limited Purpose Cash Investment Fund, 4.13% (26.8%), Fannie Mae Pool Fm9530 2.50% 7/1/2051 (7.6%), Goldman Sachs Financial Square Treasury Instruments Fund, Institutional Shares, 3.93% (1.2%), U.S. Treasury Inflation-Linked Notes 2.13%, 1/15/2035 (0.8%), Novartis Ag Chf0.49 (Regd) (0.5%). View all QHFRX holdings, sector breakdown, or dividend history.

QHFRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. QHFRX alternatives are available via the screener, along with tax-loss harvesting opportunities.